Abstract
In the present study we investigated the effect of a potent anti-inflammatory cytokine, interleukin (IL)-10, on the development of collagen-induced arthritis (CIA) in mice. Each DBA1/J mouse was immunized with 200 μg of native collagen and followed by booster injections at 3 weeks. rmIL-10 was injected i.p. daily at a dose of 100 ng/mouse. Mice were divided into four groups according to the administration period of rmIL-10. As a result, a 48-day course of IL-10 treatment significantly suppressed the severity of arthritis. Among the 4 groups, the most pronounced suppression was observed in the group in which IL-10 was given from day 0 to 21. On the other hand, there were no significant differences in the serum IgG anti-type II collagen (CII) titers between the four groups. Moreover, the production of cytokines (IL-6 and tumor necrosis factor-α (TNF-α)) and other mediators (prostaglandin E2 (PGE2) and nitric oxide (NO)) by peritoneal macrophages seemed to show no clear correlation with the severity of arthritis in mice. These results raise the possibility that IL-10 might be a useful agent for suppressing the progression and the development of CIA in mice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harris ED, Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277–89.
Di Giovine FS, Nuki G, Duff GW. Tumor necrosis factor in synovial exudates. Ann Rheum Dis 1988;47:768–72.
Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumour necrosis factor α but not tumour necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthr Rheum 1988;31:1041–5.
Miyasaka N, Sato K, Goto M. Augmented interleukin 1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthr Rheum 1988;31:480–6.
Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797–801.
Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations in arthritis. J Clin Invest 1989;83:585–92.
Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in the synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthr Rheum 1991;34:1125–32.
Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann LM, et al. Localization of interleukin 1α (IL-1α), type 1 IL-1 receptor and interleukin 1 receptor antagonist protein in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheum 1992;31:801–9.
Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991;21:2575–9.
Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthr Rheum 1993;36:1305–14.
Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauder W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510–4.
Kresina TF. A contra-IL-2 cytokine derived from mice suppressed for collagen-induced arthritis. Cell Immunol 1990;125:171–82.
Fiorentino DF, Zlotonik A, Mossmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815–22.
Niiro H, Otsuka T, Kuga S, Nemoto Y, Abe M, Hara N, et al. IL-10 inhibits prostaglandin E2 production by lipopolysaccharide-stimulated monocytes. Int Immunol 1994;6:661–4.
Niho Y, Niiro H, Kuga S, Nemoto Y, Otsuka T. Interleukin-10 inhibits functions of activated human monocytes. Vol 3. In: Abraham NG, Shadduck RK, Levine AS, Takaku F, editors. Molecular Biology of Haematopoieses Andover: Intercept, 1994:621–32.
Malefyt RDW, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992;4:314–20.
Malefyt RDW, Haanen J, Spits H, Roncarolo MG, Velde AT, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915–24.
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3441–51.
Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 1993;151:5666–74.
Bean ADG, Freiberg RA, Andrade S, Menon S, Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993;61:4937–9.
Allen JB, Costa HL, Bienkowski MJ, Wahl SM. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993;151:4344–51.
Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, et al. Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. Arthr Rheum 1994;37:406–13.
Myers LK, Seyer JM, Stuart JM, Terato K, David CS, Kang AH. T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J Immunol 1993;151:500–5.
Green LC, de Luzuriaga KR, Wagner DA, Rand W, Istfan N, Young VR, et al. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981;78:7764–8.
Peterman GM, Spencer C, Sperling AI, Bluestone JA. Role of γδ T cells in murine collagen-induced arthritis. J Immunol 1993;151:6546–58.
Rousset F, Garcia E, Defrance T, Peronne C, Hsu DH, Kastelein R, Moore KW, Banchereau J. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890–3.
Bliven ML, Wooley PH, Pepys MB, Otterness IG. Murine type II collagen arthritis: association of an acute-phase response with clinical course. Arthr Rheum 1986;29:1131–8.
Katsikis KD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517–27.
Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992;149:1054–62.
Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthr Rheum 1992;35:1160–9.
Brennan FM, Chantry D, Turner M, Foxwell B, Maini RN, Feldmann M. Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 1990;81:278–85.
Author information
Authors and Affiliations
Additional information
accepted by M. Katori
Rights and permissions
About this article
Cite this article
Tanaka, Y., Otsuka, T., Hotokebuchi, T. et al. Effect of IL-10 on collagen-induced arthritis in mice. Inflamm Res 45, 283–288 (1996). https://doi.org/10.1007/BF02280992
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02280992